R. Blaine Easley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
R. Blaine Easley has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Brett A. Simon
4 shared publicationsJoseph D. Tobias
Departments of Anesthesiology and Pediatrics, University of Iowa School of Medicine, Iowa City, IA
3 shared publicationsKenneth M. Brady
3 shared publications- Ana Fernandez-Bustamante
Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado
2 shared publications Christopher T. Lancaster
Pediatric Critical Care Fellow
2 shared publicationsJason W. Custer
Pediatric Critical Care Fellow, Departments of Anesthesiology/Critical Care Medicine and Pediatrics
2 shared publications
Latest Publications
- 1 October 2012
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 56 (5) , 209-210
Predicting the Limits of Cerebral Autoregulation During Cardiopulmonary Bypass
- 1 October 2012
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 56 (5) , 209-210
Predicting the Limits of Cerebral Autoregulation During Cardiopulmonary Bypass
- 1 June 2010
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 112 (6) , 1541-1542
Transpulmonary Determination of Extravascular Lung Water: What You See Is What You Get and It's Useful
We appreciate the interest of Drs. Phillips and Perel in our recent article.1 However, they seem to have focused on whether there exists a numeric equivalence between extravascular lung water (EVLW) measured by computed tomography tissue volume and the transpulmonary thermodilution method (EVLWTPT). Any such equivalence between these values is as much coincidence as anything else, because it has been shown by Kirov et al. 2 that a species-specific correction is required to calibrate the EVLWTPTmeasurement to accurately reflect gravimetric EVLW. We used the unmodified values from the PiCCO® device (Pulsion Medical Systems, Munich, Germany) because no validated canine correction factors are available. However, because this correction is linear, we believed that the changes in EVLWTPTwould be reasonable to follow, and, as we described, the changes in each of these measures after lipopolysaccharide administration were very different. Our goal, however, was not to perform yet another validation of EVLWTPTbut to gain insight into the pathophysiologic mechanisms that might impact the reliability of the measured EVLWTPT. Phillips and Perel apparently agree that the EVLWTPTincreased after lipopolysaccharide while EVLW measured by computed tomography did not. Even if lipopolysaccharide administration caused an increase in the actual EVLW in the short time between administration and imaging, they offer no explanation as to why this was not evident on whole lung computed tomography imaging, which despite their objections is widely accepted as a sensitive and specific measure of lung mass.3,4 On the basis of the changing perfusion distribution observed, we interpreted this divergence of the two measurements to reflect an acute change in the perfused thermal mass, resulting in an artifactual increase in the EVLWTPT.
- 1 June 2010
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 112 (6) , 1541-1542
Transpulmonary Determination of Extravascular Lung Water: What You See Is What You Get and It's Useful
We appreciate the interest of Drs. Phillips and Perel in our recent article.1 However, they seem to have focused on whether there exists a numeric equivalence between extravascular lung water (EVLW) measured by computed tomography tissue volume and the transpulmonary thermodilution method (EVLWTPT). Any such equivalence between these values is as much coincidence as anything else, because it has been shown by Kirov et al. 2 that a species-specific correction is required to calibrate the EVLWTPTmeasurement to accurately reflect gravimetric EVLW. We used the unmodified values from the PiCCO® device (Pulsion Medical Systems, Munich, Germany) because no validated canine correction factors are available. However, because this correction is linear, we believed that the changes in EVLWTPTwould be reasonable to follow, and, as we described, the changes in each of these measures after lipopolysaccharide administration were very different. Our goal, however, was not to perform yet another validation of EVLWTPTbut to gain insight into the pathophysiologic mechanisms that might impact the reliability of the measured EVLWTPT. Phillips and Perel apparently agree that the EVLWTPTincreased after lipopolysaccharide while EVLW measured by computed tomography did not. Even if lipopolysaccharide administration caused an increase in the actual EVLW in the short time between administration and imaging, they offer no explanation as to why this was not evident on whole lung computed tomography imaging, which despite their objections is widely accepted as a sensitive and specific measure of lung mass.3,4 On the basis of the changing perfusion distribution observed, we interpreted this divergence of the two measurements to reflect an acute change in the perfused thermal mass, resulting in an artifactual increase in the EVLWTPT.
- Open Access
- 1 November 2009
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 111 (5) , 1065-1074
Redistribution of Pulmonary Blood Flow Impacts Thermodilution-based Extravascular Lung Water Measurements in a Model of Acute Lung Injury
Background: Studies using transthoracic thermodilution have demonstrated increased extravascular lung water (EVLW) measurements attributed to progression of edema and flooding during sepsis and acute lung injury. The authors hypothesized that redistribution of pulmonary blood flow can cause increased apparent EVLW secondary to increased perfusion of thermally silent tissue, not increased lung edema. Methods: Anesthetized, mechanically ventilated canines were instrumented with PiCCO (Pulsion Medical, Munich, Germany) catheters and underwent lung injury by repetitive saline lavage. Hemodynamic and respiratory physiologic data were recorded. After stabilized lung injury, endotoxin was administered to inactivate hypoxic pulmonary vasoconstriction. Computed tomographic imaging was performed to quantify in vivo lung volume, total tissue (fluid) and air content, and regional distribution of blood flow. Results: Lavage injury caused an increase in airway pressures and decreased arterial oxygen content with minimal hemodynamic effects. EVLW and shunt fraction increased after injury and then markedly after endotoxin administration. Computed tomographic measurements quantified an endotoxin-induced increase in pulmonary blood flow to poorly aerated regions with no change in total lung tissue volume. Conclusions: The abrupt increase in EVLW and shunt fraction after endotoxin administration is consistent with inactivation of hypoxic pulmonary vasoconstriction and increased perfusion to already flooded lung regions that were previously thermally silent. Computed tomographic studies further demonstrate in vivo alterations in regional blood flow (but not lung water) and account for these alterations in shunt fraction and EVLW.
- 1 November 2009
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 111 (5) , 1065-1074
Open AccessRedistribution of Pulmonary Blood Flow Impacts Thermodilution-based Extravascular Lung Water Measurements in a Model of Acute Lung Injury
Background: Studies using transthoracic thermodilution have demonstrated increased extravascular lung water (EVLW) measurements attributed to progression of edema and flooding during sepsis and acute lung injury. The authors hypothesized that redistribution of pulmonary blood flow can cause increased apparent EVLW secondary to increased perfusion of thermally silent tissue, not increased lung edema. Methods: Anesthetized, mechanically ventilated canines were instrumented with PiCCO (Pulsion Medical, Munich, Germany) catheters and underwent lung injury by repetitive saline lavage. Hemodynamic and respiratory physiologic data were recorded. After stabilized lung injury, endotoxin was administered to inactivate hypoxic pulmonary vasoconstriction. Computed tomographic imaging was performed to quantify in vivo lung volume, total tissue (fluid) and air content, and regional distribution of blood flow. Results: Lavage injury caused an increase in airway pressures and decreased arterial oxygen content with minimal hemodynamic effects. EVLW and shunt fraction increased after injury and then markedly after endotoxin administration. Computed tomographic measurements quantified an endotoxin-induced increase in pulmonary blood flow to poorly aerated regions with no change in total lung tissue volume. Conclusions: The abrupt increase in EVLW and shunt fraction after endotoxin administration is consistent with inactivation of hypoxic pulmonary vasoconstriction and increased perfusion to already flooded lung regions that were previously thermally silent. Computed tomographic studies further demonstrate in vivo alterations in regional blood flow (but not lung water) and account for these alterations in shunt fraction and EVLW.
- 1 January 2009
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 165 (1) , 54-60
Total and regional lung volume changes during high-frequency oscillatory ventilation (HFOV) of the normal lung
- 1 January 2009
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 165 (1) , 54-60
Total and regional lung volume changes during high-frequency oscillatory ventilation (HFOV) of the normal lung
- Open Access
- 22 September 2008
- Published by Springer Nature in Journal of Inflammation
- Vol. 5 (1) , 15
Augmentation of Pulmonary Epithelial Cell IL-8 Expression and Permeability by Pre-B-cell Colony Enhancing Factor
Previous studies in our lab have identified Pre-B-cell colony enhancing factor (PBEF) as a novel biomarker in acute lung injury (ALI). The molecular mechanism of PBEF involvement in the pathogenesis of ALI is still incompletely understood. This study examined the role of PBEF in regulating pulmonary alveolar epithelial cell IL-8 expression and permeability.
- 22 September 2008
- Published by Springer Nature in Journal of Inflammation
- Vol. 5 (1) , 15
Open AccessAugmentation of Pulmonary Epithelial Cell IL-8 Expression and Permeability by Pre-B-cell Colony Enhancing Factor
Previous studies in our lab have identified Pre-B-cell colony enhancing factor (PBEF) as a novel biomarker in acute lung injury (ALI). The molecular mechanism of PBEF involvement in the pathogenesis of ALI is still incompletely understood. This study examined the role of PBEF in regulating pulmonary alveolar epithelial cell IL-8 expression and permeability.
- Open Access
- 1 May 2008
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 4 (2) , 123-139
Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Neurologic injury in patients with congenital heart disease remains an important source of morbidity and mortality. Advances in surgical repair and perioperative management have resulted in longer life expectancies for these patients. Current practice and research must focus on identifying treatable risk factors for neurocognitive dysfunction, advancing methods for perioperative neuromonitoring, and refining treatment and care of the congenital heart patient with potential neurologic injury. Techniques for neuromonitoring and future directions will be discussed.
- 1 May 2008
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 4 (2) , 123-139
Open AccessNeurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Neurologic injury in patients with congenital heart disease remains an important source of morbidity and mortality. Advances in surgical repair and perioperative management have resulted in longer life expectancies for these patients. Current practice and research must focus on identifying treatable risk factors for neurocognitive dysfunction, advancing methods for perioperative neuromonitoring, and refining treatment and care of the congenital heart patient with potential neurologic injury. Techniques for neuromonitoring and future directions will be discussed.
- 1 February 2008
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 22 (1) , 147-151
Pro: Dexmedetomidine Should Be Used for Infants and Children Undergoing Cardiac Surgery
- 1 February 2008
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 22 (1) , 147-151
Pro: Dexmedetomidine Should Be Used for Infants and Children Undergoing Cardiac Surgery
- 24 November 2006
- Published by Wiley in Pediatric Anesthesia
- Vol. 17 (4) , 341-346
Dexmedetomidine for the treatment of postanesthesia shivering in children
Summary: Background: Shivering is a common postanesthesia adverse event with multiple etiologies and multiple suggested prophylactic and abortive treatment regimens. Dexmedetomidine, a centrally acting α2‐adrenergic agonist, has been used as a sedative agent and is known to reduce the shivering threshold. We hypothesized that children with postanesthesia shivering would reduce shivering behavior following a single bolus dose of dexmedetomidine.Methods: Dexmedetomidine was administered in a prospective, open‐label fashion. The anesthesia management was uniform consisting of maintenance inhaled anesthesia (sevoflurane) and the intraoperative administration of fentanyl (1–2 μg·kg−1) plus a regional anesthetic technique (either a neuraxial or peripheral block) for postoperative analgesia. Criteria for treatment included: (i) shivering, (ii) successful extubation, and (iii) no other complaint/indication of pain. All children who met the criteria were treated with a single intravenous bolus dose of dexmedetomidine (0.5 μg·kg−1) over 3–5 min. Following the completion of drug administration, shivering activity was recorded every minute (up to 10 min) with any adverse effects or complaints. The efficacy of shivering reduction at 5 min in this cohort is compared with previous reports from the literature of the efficacy of clonidine and meperidine.Results: Twenty‐four children ranging in age from 7 to 16 years (11.5 ± 2.5 years) were treated. All children had a cessation of shivering behavior within 5 min following the completion of dexmedetomidine administration. The onset of effect was 3.5 ± 0.9 min. No adverse effects were observed. No shivering behavior recurred.Conclusions: This study demonstrates the efficacy of dexmedetomidine in the treatment of postanesthesia shivering.
- 24 November 2006
- Published by Wiley in Pediatric Anesthesia
- Vol. 17 (4) , 341-346
Dexmedetomidine for the treatment of postanesthesia shivering in children
Summary: Background: Shivering is a common postanesthesia adverse event with multiple etiologies and multiple suggested prophylactic and abortive treatment regimens. Dexmedetomidine, a centrally acting α2‐adrenergic agonist, has been used as a sedative agent and is known to reduce the shivering threshold. We hypothesized that children with postanesthesia shivering would reduce shivering behavior following a single bolus dose of dexmedetomidine.Methods: Dexmedetomidine was administered in a prospective, open‐label fashion. The anesthesia management was uniform consisting of maintenance inhaled anesthesia (sevoflurane) and the intraoperative administration of fentanyl (1–2 μg·kg−1) plus a regional anesthetic technique (either a neuraxial or peripheral block) for postoperative analgesia. Criteria for treatment included: (i) shivering, (ii) successful extubation, and (iii) no other complaint/indication of pain. All children who met the criteria were treated with a single intravenous bolus dose of dexmedetomidine (0.5 μg·kg−1) over 3–5 min. Following the completion of drug administration, shivering activity was recorded every minute (up to 10 min) with any adverse effects or complaints. The efficacy of shivering reduction at 5 min in this cohort is compared with previous reports from the literature of the efficacy of clonidine and meperidine.Results: Twenty‐four children ranging in age from 7 to 16 years (11.5 ± 2.5 years) were treated. All children had a cessation of shivering behavior within 5 min following the completion of dexmedetomidine administration. The onset of effect was 3.5 ± 0.9 min. No adverse effects were observed. No shivering behavior recurred.Conclusions: This study demonstrates the efficacy of dexmedetomidine in the treatment of postanesthesia shivering.
- 14 August 2006
- Published by Wiley in Pediatric Anesthesia
- Vol. 16 (10) , 1042-1046
Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage
Summary: Background: Recombinant activated factor VII (rFVIIa) is approved by the FDA for the treatment of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX. In addition to the FDA‐approved indications, rFVIIa has been anecdotally reported effective for profound bleeding episodes in adult patients without hemophilia, and proven beneficial for adults with intracranial hemorrhage. In the pediatric literature, case reports have been made with apparent clinical improvement seen after the use of rFVIIa for acute life‐threatening bleeding; however, there are limited data regarding its use in infants Methods: This case series of infants under 4 months with coagulopathy and bleeding treated with rFVIIa was collected from two institutions. We report the age, weight and pre‐rFVIIa laboratory values of the patients as well as the clinical scenario and outcomes.Results: The nine infants all suffered acute life‐threatening hemorrhage. Two patients were postoperative from cardiac surgery, two with Vitamin K deficiency and intracranial hemorrhage, three with suspected necrotizing enterocolitis and abdominal hemorrhage, and two with pulmonary hemorrhage. The patients ranged in age from 2 days to 4 months, (average age 1 month and average weight 3.3 ± 1.0 kg). Seven of the nine patients had frozen plasma, cryoprecipitate, or platelet administration in failed attempts to correct the coagulation defect prior to receiving rFVIIa. The dose range used in this series was 90–100 μg·kg−1, with 90 μg·kg−1 being the most commonly used dose. The average pre‐rFVIIa INR was 8.7 ± 5.1. Four patients had an immeasurably high INR. All patients had clinical resolution of bleeding after receiving rFVIIa, and seven of nine patients survived.Conclusions: rFVIIa is a powerful hemostatic drug whose mechanism of action provides a theoretical specificity to sites of tissue injury. In addition to its FDA‐approved uses in hemophiliac patients, this drug has a potential role in the treatment of life‐threatening hemorrhage from multiple causes.
- 14 August 2006
- Published by Wiley in Pediatric Anesthesia
- Vol. 16 (10) , 1042-1046
Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage
Summary: Background: Recombinant activated factor VII (rFVIIa) is approved by the FDA for the treatment of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX. In addition to the FDA‐approved indications, rFVIIa has been anecdotally reported effective for profound bleeding episodes in adult patients without hemophilia, and proven beneficial for adults with intracranial hemorrhage. In the pediatric literature, case reports have been made with apparent clinical improvement seen after the use of rFVIIa for acute life‐threatening bleeding; however, there are limited data regarding its use in infants Methods: This case series of infants under 4 months with coagulopathy and bleeding treated with rFVIIa was collected from two institutions. We report the age, weight and pre‐rFVIIa laboratory values of the patients as well as the clinical scenario and outcomes.Results: The nine infants all suffered acute life‐threatening hemorrhage. Two patients were postoperative from cardiac surgery, two with Vitamin K deficiency and intracranial hemorrhage, three with suspected necrotizing enterocolitis and abdominal hemorrhage, and two with pulmonary hemorrhage. The patients ranged in age from 2 days to 4 months, (average age 1 month and average weight 3.3 ± 1.0 kg). Seven of the nine patients had frozen plasma, cryoprecipitate, or platelet administration in failed attempts to correct the coagulation defect prior to receiving rFVIIa. The dose range used in this series was 90–100 μg·kg−1, with 90 μg·kg−1 being the most commonly used dose. The average pre‐rFVIIa INR was 8.7 ± 5.1. Four patients had an immeasurably high INR. All patients had clinical resolution of bleeding after receiving rFVIIa, and seven of nine patients survived.Conclusions: rFVIIa is a powerful hemostatic drug whose mechanism of action provides a theoretical specificity to sites of tissue injury. In addition to its FDA‐approved uses in hemophiliac patients, this drug has a potential role in the treatment of life‐threatening hemorrhage from multiple causes.
- 1 July 2006
- Published by Elsevier in Academic Radiology
- Vol. 13 (7) , 916-921
Mechanism of Hypoxemia in Acute Lung Injury Evaluated by Multidetector-Row CT
- 1 July 2006
- Published by Elsevier in Academic Radiology
- Vol. 13 (7) , 916-921
Mechanism of Hypoxemia in Acute Lung Injury Evaluated by Multidetector-Row CT